Antivascular endothelial growth factor in hereditary dystrophies.
Choroidal neovascularization can rarely complicate the course of a number of chorioretinal hereditary dystrophies leading to an even further impaired vision function. In recent years, several case reports and case series have shown that intravitreal injections of antivascular endothelial growth factor drugs can be effective in treating subfoveal choroidal neovascularization secondary to chorioretinal dystrophies either improving vision, or at least halting its progressive loss. Additional studies are warranted to confirm the initial positive response and to assess the best therapeutic regimen.
Battaglia Parodi
Maurizio
M
Iacono
Pierluigi
P
Bandello
Francesco
F
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D059327:Brachydactyly; D015862:Choroid Diseases / Q000150:complications* / Q000235:genetics*; D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D003103:Coloboma / Q000150:complications; D018450:Disease Progression; D005532:Foot Deformities, Congenital / Q000150:complications; D006228:Hand Deformities, Congenital / Q000150:complications; D006801:Humans; D056965:Injections, Intraocular; D012164:Retinal Diseases / Q000150:complications* / Q000235:genetics*; D012174:Retinitis Pigmentosa / Q000150:complications; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity / Q000187:drug effects; D057826:Vitelliform Macular Dystrophy / Q000150:complications; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A